Symbols / ARWR $58.10 -1.86%
ARWR Chart
About
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.14B |
| Enterprise Value | 7.91B | Income | 202.26M | Sales | 1.09B |
| Book/sh | 4.14 | Cash/sh | 6.53 | Dividend Yield | — |
| Payout | 0.00% | Employees | 711 | IPO | — |
| P/E | 36.31 | Forward P/E | -13.52 | PEG | — |
| P/S | 7.46 | P/B | 14.04 | P/C | — |
| EV/EBITDA | 24.30 | EV/Sales | 7.25 | Quick Ratio | 3.26 |
| Current Ratio | 3.38 | Debt/Eq | 124.07 | LT Debt/Eq | — |
| EPS (ttm) | 1.60 | EPS next Y | -4.30 | EPS Growth | — |
| Revenue Growth | 104.61% | Earnings | 2026-05-11 | ROA | 14.35% |
| ROE | 75.50% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | 15.46% | Profit Margin | 18.54% | Shs Outstand | 140.03M |
| Shs Float | 122.04M | Short Float | 10.79% | Short Ratio | 3.25 |
| Short Interest | — | 52W High | 76.76 | 52W Low | 9.57 |
| Beta | 1.30 | Avg Volume | 2.83M | Volume | 2.81M |
| Target Price | $81.36 | Recom | Buy | Prev Close | $59.20 |
| Price | $58.10 | Change | -1.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$81.36
Mean price target
2. Current target
$58.10
Latest analyst target
3. DCF / Fair value
$21.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$58.10
Low
$35.00
High
$110.00
Mean
$81.36
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-01-22 | main | B. Riley Securities | Buy → Buy | $101 |
| 2026-01-21 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-01-13 | reit | Piper Sandler | Overweight → Overweight | $110 |
| 2026-01-07 | main | Goldman Sachs | Neutral → Neutral | $85 |
| 2026-01-07 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $81 |
| 2026-01-07 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-12-17 | main | Piper Sandler | Overweight → Overweight | $100 |
| 2025-12-11 | main | RBC Capital | Outperform → Outperform | $80 |
| 2025-12-09 | main | B of A Securities | Buy → Buy | $81 |
| 2025-12-02 | main | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-12-01 | main | B of A Securities | Buy → Buy | $62 |
| 2025-12-01 | main | Chardan Capital | Buy → Buy | $60 |
| 2025-11-26 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $48 |
| 2025-11-20 | main | Goldman Sachs | Neutral → Neutral | $48 |
| 2025-11-19 | main | RBC Capital | Outperform → Outperform | $52 |
| 2025-11-19 | main | Chardan Capital | Buy → Buy | $60 |
| 2025-11-19 | main | Piper Sandler | Overweight → Overweight | $70 |
| 2025-11-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $45 |
| 2025-10-08 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
- Arrowhead Pharma plans four March healthcare investor events - Stock Titan ue, 24 Feb 2026 12
- Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals? - simplywall.st ue, 10 Mar 2026 07
- Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC - MarketBeat Sat, 07 Mar 2026 10
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance Sat, 28 Feb 2026 08
- Fund Update: New $10.6M $ARWR stock position opened by Skandinaviska Enskilda Banken AB (publ) - Quiver Quantitative hu, 12 Feb 2026 08
- Hamilton James, Arrowhead Pharmaceuticals CMO, sells $641,900 in stock - Investing.com Mon, 09 Mar 2026 23
- (ARWR) and the Role of Price-Sensitive Allocations - Stock Traders Daily Fri, 06 Mar 2026 08
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 10,000 Shares - MarketBeat ue, 10 Mar 2026 00
- ARWR - Arrowhead Pharma Latest Stock News & Market Updates - Stock Titan ue, 27 Jan 2026 08
- ARROWHEAD PHARMACEUTICALS Earnings Preview: Recent $ARWR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Sun, 23 Nov 2025 08
- Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Intrinsic Value Is Potentially 72% Above Its Share Price - Yahoo Finance Wed, 01 Oct 2025 07
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry - simplywall.st ue, 02 Dec 2025 08
- Arrowhead Pharma (NASDAQ: ARWR) posts $829M FY 2025 revenue, wins first FDA nod - Stock Titan ue, 25 Nov 2025 08
- Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp - MarketBeat Sat, 21 Feb 2026 08
- Arrowhead Pharma to reveal fiscal Q1 2026 results in Feb. 5 webcast - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 641900 | — | Sale at price 64.19 per share. | HAMILTON JAMES C | Officer | — | 2026-03-05 00:00:00 | D |
| 1 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | O'BRIEN PATRICK C | Chief Operating Officer | — | 2026-01-06 00:00:00 | D |
| 2 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | HAMILTON JAMES C | Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | APEL DANIEL JOSEPH | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 4 | 2500 | — | — | Stock Gift at price 0.00 per share. | O'BRIEN PATRICK C | Chief Operating Officer | — | 2026-01-06 00:00:00 | D |
| 5 | 49493 | 3123349 | — | Sale at price 61.12 - 68.00 per share. | O'BRIEN PATRICK C | Chief Operating Officer | — | 2026-01-05 00:00:00 | D |
| 6 | 40164 | 2534661 | — | Sale at price 61.24 - 68.00 per share. | HAMILTON JAMES C | Officer | — | 2026-01-05 00:00:00 | D |
| 7 | 13187 | 871703 | — | Sale at price 65.88 - 66.39 per share. | ANZALONE CHRISTOPHER RICHARD | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 8 | 2800 | — | — | Stock Gift at price 0.00 per share. | O'BRIEN PATRICK C | Chief Operating Officer | — | 2025-12-31 00:00:00 | D |
| 9 | 51726 | 3575575 | — | Sale at price 68.69 - 69.33 per share. | ANZALONE CHRISTOPHER RICHARD | Chief Executive Officer | — | 2025-12-29 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.21 |
| NormalizedEBITDA | 164.82M | -561.51M | -175.67M | -162.29M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.63M | -599.49M | -205.28M | -176.06M |
| ReconciledDepreciation | 23.93M | 18.59M | 12.49M | 10.42M |
| EBITDA | 164.82M | -561.51M | -175.67M | -162.29M |
| EBIT | 140.89M | -580.11M | -188.16M | -172.71M |
| NetInterestIncome | -52.07M | -9.63M | -3.03M | 5.03M |
| InterestExpense | 89.36M | 32.35M | 18.33M | 0.00 |
| InterestIncome | 37.29M | 22.72M | 15.30M | 5.03M |
| NormalizedIncome | -1.63M | -599.49M | -205.28M | -176.06M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.63M | -599.49M | -205.28M | -176.06M |
| TotalExpenses | 731.10M | 604.63M | 445.74M | 421.74M |
| TotalOperatingIncomeAsReported | 98.35M | -601.08M | -205.00M | -178.51M |
| DilutedAverageShares | 133.76M | 119.78M | 107.31M | 105.96M |
| BasicAverageShares | 133.76M | 119.78M | 107.31M | 105.96M |
| DilutedEPS | -0.01 | -5.00 | -1.92 | -1.67 |
| BasicEPS | -0.01 | -5.00 | -1.91 | -1.63 |
| DilutedNIAvailtoComStockholders | -1.63M | -599.49M | -205.28M | -176.06M |
| NetIncomeCommonStockholders | -1.63M | -599.49M | -205.28M | -176.06M |
| NetIncome | -1.63M | -599.49M | -205.28M | -176.06M |
| MinorityInterests | -31.75M | 10.20M | 4.00M | 431.00K |
| NetIncomeIncludingNoncontrollingInterests | 30.11M | -609.69M | -209.28M | -176.49M |
| NetIncomeContinuousOperations | 30.11M | -609.69M | -209.28M | -176.49M |
| TaxProvision | 21.42M | -2.77M | 2.78M | 3.79M |
| PretaxIncome | 51.53M | -612.46M | -206.49M | -172.71M |
| OtherIncomeExpense | 5.26M | -1.75M | 1.54M | 765.00K |
| OtherNonOperatingIncomeExpenses | 5.26M | -1.75M | 1.54M | 765.00K |
| NetNonOperatingInterestIncomeExpense | -52.07M | -9.63M | -3.03M | 5.03M |
| TotalOtherFinanceCost | -5.03M | -6.12M | ||
| InterestExpenseNonOperating | 89.36M | 32.35M | 18.33M | 0.00 |
| InterestIncomeNonOperating | 37.29M | 22.72M | 15.30M | 5.03M |
| OperatingIncome | 98.35M | -601.08M | -205.00M | -178.51M |
| OperatingExpense | 731.10M | 604.63M | 445.74M | 421.74M |
| DepreciationAmortizationDepletionIncomeStatement | 2.03M | 1.94M | 1.62M | 1.61M |
| DepreciationAndAmortizationInIncomeStatement | 2.03M | 1.94M | 1.62M | 1.61M |
| ResearchAndDevelopment | 607.16M | 505.87M | 353.19M | 297.31M |
| SellingGeneralAndAdministration | 121.92M | 96.82M | 90.93M | 124.43M |
| GeneralAndAdministrativeExpense | 121.92M | 96.82M | 90.93M | 124.43M |
| OtherGandA | 59.21M | 28.85M | 24.14M | 124.43M |
| SalariesAndWages | 62.70M | 67.97M | 66.80M | 105.17M |
| TotalRevenue | 829.45M | 3.55M | 240.74M | 243.23M |
| OperatingRevenue | 829.45M | 3.55M | 240.74M | 243.23M |
| Line Item | 2025-09-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 2.66M | |||
| OrdinarySharesNumber | 135.70M | 124.38M | 107.31M | 105.96M |
| ShareIssued | 138.36M | 124.38M | 107.31M | 105.96M |
| NetDebt | 166.18M | 316.98M | ||
| TotalDebt | 366.28M | 510.55M | 115.17M | 81.58M |
| TangibleBookValue | 459.19M | 176.88M | 261.08M | 386.56M |
| InvestedCapital | 720.93M | 578.63M | 271.34M | 398.52M |
| WorkingCapital | 755.15M | 592.30M | 311.02M | 266.45M |
| NetTangibleAssets | 459.19M | 176.88M | 261.08M | 386.56M |
| CapitalLeaseObligations | 111.40M | 117.37M | 115.17M | 81.58M |
| CommonStockEquity | 466.05M | 185.44M | 271.34M | 398.52M |
| TotalCapitalization | 680.93M | 578.63M | 271.34M | 398.52M |
| TotalEquityGrossMinorityInterest | 503.42M | 191.06M | 287.16M | 418.34M |
| MinorityInterest | 37.36M | 5.62M | 15.82M | 19.82M |
| StockholdersEquity | 466.05M | 185.44M | 271.34M | 398.52M |
| GainsLossesNotAffectingRetainedEarnings | 6.44M | 4.75M | -3.22M | -136.00K |
| OtherEquityAdjustments | 6.44M | 4.75M | -3.22M | -136.00K |
| TreasuryStock | 53.19M | 0.00 | ||
| RetainedEarnings | -1.63B | -1.63B | -1.03B | -820.75M |
| AdditionalPaidInCapital | 2.14B | 1.81B | 1.30B | 1.22B |
| CapitalStock | 231.00K | 217.00K | 200.00K | 198.00K |
| CommonStock | 231.00K | 217.00K | 200.00K | 198.00K |
| TotalLiabilitiesNetMinorityInterest | 881.88M | 948.74M | 478.39M | 273.60M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 686.39M | 845.57M | 372.93M | 134.75M |
| LiabilitiesHeldforSaleNonCurrent | 367.40M | 341.36M | 268.33M | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 55.95M | 131.50M | |
| NonCurrentDeferredRevenue | 0.00 | 55.95M | 131.50M | |
| LongTermDebtAndCapitalLeaseObligation | 319.00M | 504.21M | 104.61M | 78.80M |
| LongTermCapitalLeaseObligation | 104.11M | 111.03M | 104.61M | 78.80M |
| LongTermDebt | 214.88M | 393.18M | ||
| CurrentLiabilities | 195.49M | 103.17M | 105.46M | 138.85M |
| OtherCurrentLiabilities | 10.81M | 432.00K | 435.00K | |
| CurrentDeferredLiabilities | 2.40M | 0.00 | 866.00K | 74.10M |
| CurrentDeferredRevenue | 2.40M | 0.00 | 866.00K | 74.10M |
| CurrentDebtAndCapitalLeaseObligation | 47.29M | 6.34M | 10.56M | 2.78M |
| CurrentCapitalLeaseObligation | 7.29M | 6.34M | 10.56M | 2.78M |
| CurrentDebt | 40.00M | |||
| OtherCurrentBorrowings | 40.00M | |||
| PayablesAndAccruedExpenses | 134.99M | 96.39M | 93.59M | 61.98M |
| CurrentAccruedExpenses | 117.31M | 85.01M | 57.73M | 59.11M |
| Payables | 17.67M | 11.39M | 35.87M | 2.87M |
| AccountsPayable | 17.67M | 11.39M | 35.87M | 2.87M |
| TotalAssets | 1.39B | 1.14B | 765.55M | 691.94M |
| TotalNonCurrentAssets | 434.66M | 444.33M | 349.08M | 286.64M |
| OtherNonCurrentAssets | 1.39M | 4.48M | 3.26M | 218.00K |
| InvestmentsAndAdvances | 0.00 | 105.87M | 245.59M | |
| InvestmentinFinancialAssets | 0.00 | 105.87M | 245.59M | |
| HeldToMaturitySecurities | 0.00 | 105.87M | 245.59M | |
| GoodwillAndOtherIntangibleAssets | 6.86M | 8.56M | 10.26M | 11.96M |
| OtherIntangibleAssets | 6.86M | 8.56M | 10.26M | 11.96M |
| NetPPE | 426.41M | 431.29M | 335.56M | 168.59M |
| AccumulatedDepreciation | -80.17M | -58.02M | -41.95M | -31.55M |
| GrossPPE | 506.57M | 489.31M | 377.51M | 200.14M |
| Leases | 104.42M | 104.41M | 103.81M | 42.02M |
| ConstructionInProgress | 15.94M | 188.73M | 166.66M | 56.37M |
| OtherProperties | 125.24M | 110.61M | 101.81M | 96.57M |
| MachineryFurnitureEquipment | 6.66M | 6.58M | 2.24M | 2.18M |
| BuildingsAndImprovements | 251.32M | 75.99M | 0.00 | |
| LandAndImprovements | 3.00M | 3.00M | 3.00M | 3.00M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 950.64M | 695.47M | 416.47M | 405.30M |
| OtherCurrentAssets | 13.52M | 4.97M | 4.03M | 20.20M |
| PrepaidAssets | 10.93M | 9.54M | 8.81M | 7.29M |
| Receivables | 6.82M | 0.00 | 0.00 | 1.41M |
| AccountsReceivable | 6.82M | 0.00 | 0.00 | 1.41M |
| CashCashEquivalentsAndShortTermInvestments | 919.37M | 680.96M | 403.63M | 376.40M |
| OtherShortTermInvestments | 830.66M | 604.75M | 292.74M | 268.39M |
| CashAndCashEquivalents | 88.71M | 76.21M | 110.89M | 108.00M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | 156.89M | -604.32M | -330.63M | -188.91M |
| RepaymentOfDebt | -201.62M | 0.00 | 0.00 | 0.00 |
| IssuanceOfDebt | 10.26M | 392.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 241.39M | 429.26M | 0.00 | 0.00 |
| CapitalExpenditure | -22.67M | -141.47M | -176.74M | -52.78M |
| InterestPaidSupplementalData | 19.00K | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 3.74M | 0.00 | 2.00K | 2.00K |
| EndCashPosition | 226.55M | 102.69M | 110.89M | 108.00M |
| BeginningCashPosition | 102.69M | 110.89M | 108.00M | 184.43M |
| EffectOfExchangeRateChanges | -401.00K | 4.20M | -122.00K | -67.00K |
| ChangesInCash | 124.26M | -12.40M | 3.01M | -76.36M |
| FinancingCashFlow | 74.01M | 870.52M | 253.05M | 65.19M |
| CashFlowFromContinuingFinancingActivities | 74.01M | 870.52M | 253.05M | 65.19M |
| NetOtherFinancingCharges | -5.00M | 46.87M | 250.00M | 60.00M |
| ProceedsFromStockOptionExercised | 28.98M | 2.39M | 3.05M | 5.19M |
| NetCommonStockIssuance | 241.39M | 429.26M | 0.00 | 0.00 |
| CommonStockIssuance | 241.39M | 429.26M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -191.37M | 392.00M | 0.00 | 0.00 |
| NetShortTermDebtIssuance | 10.26M | 0.00 | 0.00 | |
| ShortTermDebtIssuance | 10.26M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -201.62M | 392.00M | 0.00 | 0.00 |
| LongTermDebtPayments | -201.62M | 0.00 | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 392.00M | 0.00 | 0.00 |
| InvestingCashFlow | -129.29M | -420.07M | -96.16M | -5.42M |
| CashFlowFromContinuingInvestingActivities | -129.29M | -420.07M | -96.16M | -5.42M |
| NetInvestmentPurchaseAndSale | -106.63M | -278.60M | 80.58M | 47.36M |
| SaleOfInvestment | 689.63M | 442.34M | 326.72M | 270.75M |
| PurchaseOfInvestment | -796.26M | -720.95M | -246.14M | -223.39M |
| NetPPEPurchaseAndSale | -22.67M | -141.47M | -176.74M | -52.78M |
| PurchaseOfPPE | -22.67M | -141.47M | -176.74M | -52.78M |
| OperatingCashFlow | 179.55M | -462.85M | -153.89M | -136.13M |
| CashFlowFromContinuingOperatingActivities | 179.55M | -462.85M | -153.89M | -136.13M |
| ChangeInWorkingCapital | -18.23M | 25.09M | -51.55M | -98.29M |
| ChangeInOtherWorkingCapital | 5.49M | -2.07M | -129.18M | -99.01M |
| ChangeInOtherCurrentLiabilities | -4.61M | 2.24M | 46.59M | |
| ChangeInPayablesAndAccruedExpense | 47.78M | 26.58M | 18.03M | 11.16M |
| ChangeInAccruedExpense | 41.50M | 32.12M | -14.96M | 17.75M |
| ChangeInPayable | 6.29M | -5.54M | 33.00M | -6.59M |
| ChangeInAccountPayable | 6.29M | -5.54M | 33.00M | -6.59M |
| ChangeInPrepaidAssets | -9.94M | -1.66M | 11.60M | -19.29M |
| ChangeInReceivables | -56.97M | 0.00 | 1.41M | 8.85M |
| ChangesInAccountReceivables | -56.97M | 0.00 | 1.41M | 8.85M |
| OtherNonCashItems | 89.36M | 32.35M | 18.33M | 2.91M |
| StockBasedCompensation | 63.37M | 73.97M | 78.13M | 120.89M |
| AmortizationOfSecurities | -5.79M | -3.24M | -2.02M | 2.91M |
| DepreciationAmortizationDepletion | 23.93M | 18.59M | 12.49M | 10.42M |
| DepreciationAndAmortization | 23.93M | 18.59M | 12.49M | 10.42M |
| OperatingGainsLosses | -3.19M | 80.00K | 4.43M | -1.71M |
| GainLossOnInvestmentSecurities | -3.19M | 80.00K | 4.43M | -1.71M |
| NetIncomeFromContinuingOperations | 30.11M | -609.69M | -209.28M | -176.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARWR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|